Group items tagged

The government has launched a new campaign over social media and radio today (January 10) to encourage pregnant women to take their first, second and third dose of Covid-19 vaccine. Joined by experts at the Royal College of Obstetricians and Gynaecologists (RCOG) and the Royal College of Midwives (RCM), the campaign highlights the risks of the infection and benefits of vaccination. According to the latest data from the UK Health Security Agency (UKHSA), Covid-19 vaccinations are safe for pregnant women. Department of Health and Social Care (DHSC) chief scientific adviser professor Lucy Chappell, said: "We have extensive evidence now to show that the vaccines are safe and that the risks posed by Covid-19 are far greater," calling upon pregnant women who have yet to have their jabs. The campaign will also run testimonies of pregnant women who have had their jabs.

Health services in the UK today (January 4) marked the first anniversary of the deployment of the Oxford University/AstraZeneca vaccine in fight against Covid-19. Exactly a year ago, the UK became the first country in the world to administer the vaccine by jabbing Brian Pinker, 82 at Oxford University Hospital. So far, around 50 million AstraZeneca vaccines have been administered to people in the UK. Commenting on the landmark day, vaccines minister Maggie Throup said: "The Oxford-AstraZeneca vaccine is a UK success story and demonstrates what can be achieved when researchers, scientists and the government work together. "The at-cost vaccine has given billions of people around the world a way to fight back against this virus." Further, she urged people to get vaccinated to protect themselves and their families this winter.

Community pharmacies saved nearly 20,000 lives up to autumn 2021 by vaccinating people against the Covid-19, the National Pharmacy Association said based on a National Audit Office (NAO) report released on Friday (February 25). The report, having taken evidence from the NPA, highlighted that community pharmacies and GPs performed far beyond expectations in delivering the Covid-19 vaccine, as 71 per cent of jabs were administered by both healthcare providers till October-end, against an initial assumption of 56 per cent. The report cited UK Health Security Agency figures, which estimated that the programme overall prevented up to 128,000 deaths and 262,000 hospitalisations by September 24 and September 19, respectively. The estimated number is considerably higher, given the pivotal role played by pharmacies in this winter's phase of the vaccination programme, the NPA stated.

More than 7,000 hospitalisations and deaths in the UK could have been averted in summer 2022 if people had received their recommended COVID-19 vaccine doses, a new study published in The Lancet has revealed. The largest ever study carried out in the UK found that between a third and a half of the UK population had not had the recommended number of COVID vaccinations and boosters by summer 2022. In Northern Ireland, nearly 50 per cent of the population were under-vaccinated, while the proportion of under-vaccinated people in England was 45.7 per cent, 34.2 per cent for Scotland and 32.8 per cent Wales. Researchers from the Health Data Research UK (HDR UK) and the University of Edinburgh analysed the electronic health records of 67 million residents aged 5 and older from across the four countries during June 1 to September 30 2022.

An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights for Covid-19 interventions between the pharmaceutical industry and developing nations endures. At the heart of the plan is a commitment to set aside part of the production of vaccines and treatments upfront for vulnerable populations in low-income countries when the next pandemic arises, given how fragmented access to Covid tools has left many populations unprotected. In order to do better next time - and without knowing which companies will develop the first drugs and vaccines for the next pandemic - having the industry collectively make this commitment is potentially transformative, said Thomas Cueni, head of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). The pledge, called the Berlin Declaration, was made on July 19 by members of the global pharmaceutical industry group that include many of the companies involved in developing Covid interventions, such as AstraZeneca, GSK, Moderna, Pfizer and Merck. The declaration is not legally binding. However, if a company that signed on reneges on its vow, it would face grave consequences in the court of public opinion, said Cueni.

The National Health Service will begin its autumn Covid vaccine program next week, a month earlier than planned in response to the spread of a new variant dubbed Pirola. Covid vaccines will be administered to care home residents and housebound individuals from Monday onwards, while over-65s and other vulnerable groups will receive their appointments the week after. On Aug. 30, NHS England shifted the autumn vaccination drive to start on September 11 in response to the new Covid-19 variant, BA.2.86, detected on August 18. The primary groups can book through a national system upon receiving an invitation from the NHS. Some people may get an earlier call from their GP, and a few have already scheduled Covid vaccinations alongside their flu jabs. The NHS will begin inviting other eligible groups from Sept. 18. However, it is important to note that not everyone will receive a call at the same time. These groups will include individuals aged 65 and over, those aged six months to 64 years in a clinical risk category, frontline health and social care workers, and individuals aged 12 to 64 who are carers or household contacts of those with immunosuppression.

A new study has revealed that the risk of death from COVID-19 decreases significantly after vaccination, but this protection diminishes after six months, providing evidence for continued booster doses. Researchers from the UK Health Security Agency (UKHSA), who analysed more than 10 million cases of COVID-19 in adults in England between May 2020 and February 2022, found a clear association between vaccination and reduced mortality. But they also highlighted a crucial timeframe - within six months of the last vaccine dose - when Case Fatality Risk (CFR) - the proportion of cases that resulted in death - was consistently at its lowest across all age groups. After this, the protective benefit of the vaccine began to wane and CFR increased.

Even as the UK agrees deals for 14 million additional vaccine doses from Moderna and Pfizer, the Royal Pharmaceutical Society has renewed its calls for community pharmacies in England to play an increased role in delivering booster jabs for Covid-19. "Pharmacists and pharmacy teams across the health service in England have been crucial to the success of the flu and Covids-19 vaccination programmes from the outset," said Thorrun Govind, chair of the RPS in England, who has been making a case on national television for an increased role of the profession. She added: "They continue to go above and beyond to support patient care, engaging with local communities and helping to overcome vaccine hesitancy. "They've already done so much this year to look after patients in really difficult circumstances, but many will be ready to rise to the challenge of this new national effort."

The Pharmacists' Defence Association (PDA) has urged pharmacists working in Covid-19 vaccination role to report any concerns about the needles and syringes supplied with the Moderna Spikevax Bivalent vaccine. The association has heard reports of bending when vaccinators pierce the top of the vial containing the Covid-19 vaccine doses, needles falling out during manipulation and appearing to be bent even before removal from the packaging. PDA has advised its members who are working in a Covid-19 vaccination role "to report any concerns via the Yellow Card medical device reporting system, and to keep up to date with NHS clinical updates for ongoing information and guidance." Current advice from the NHS includes sharing of video and poster resources (available on FutureNHS) which have been produced by the supplier to support the introduction of the new administration needles and syringes for Spikevax Bivalent. This is following a switch from BD Flu+ 23G x 25mm 1ml syringe combined needle and syringe (CNS) to the Owen Mumford Unifine Safety Retractable Needle 25G x 25mm & 1ml Syringe.

As the deadline for the frontline healthcare workers to get fully vaccinated approaches, tens of thousands of NHS staff who have not yet taken the Covid-19 vaccine face termination in just a fortnight. Although it is estimated that the majority of NHS staff have been fully jabbed, health and social care providers in England will soon be needed to ensure that all those working in areas regulated by the Care Quality Commission (CQC), are fully vaccinated against Covid-19 before the April 1, 2022. Those who are exempted from taking the vaccination do not fall under this purview. According to the NHS England guidance around Vaccination as a Condition of Deployment (VCOD) for healthcare workers, all frontline staff must have had both the doses by April 1, meaning that by February 3 the first must have been administered and the second by March 31. All unvaccinated frontline workers will be called into formal meetings from February 4 and given a warning of dismissal. Notices will then be issued from that day, with March 31 marking the end of the notice period

Britain has approved a new coronavirus vaccine by the Austrian-French drugmaker Valneva. "An approval has been granted after the Valneva Covid-19 vaccine was found to meet the required safety, quality and effectiveness standards," the Medicines and Healthcare products Regulatory Agency said in a statement on Thursday (April 14), adding: "It is also the first, whole-virus inactivated Covid-19 vaccine to gain regulatory approval in the UK." In vaccines such as Valneva's VLA2001, the virus is grown in a lab and then made completely inactive so that it cannot infect cells or replicate in the body but can still trigger an immune response. It is seen by some as having the potential to win over people wary of some which use new mRNA technology. Valneva CEO Thomas Lingelbach said that "this authorisation could pave the way for the availability of an alternative vaccine solution for the UK population."

Recent uptake of COVID-19 vaccine booster doses in Europe has been "rather disappointing," an official said on Thursday (November 24), amid concerns that protection against severe cases of the disease could weaken during the winter. The European average rate of re-vaccination, or receiving booster doses, was only 29 per cent in the groups of people considered to be at highest risk, such as the elderly and immunocompromised. "It is of concern that those most at risk of hospitalisation or severe COVID are not adequately protected," the European Medicines Agency's head of health threats and vaccines strategy, Marco Cavaleri, told a news briefing. Though there have not been major increases in COVID-19 case rates in recent weeks, Cavaleri said that could change during the colder winter months.

The government announced today (November 19) that it would add booster shots to the Covid-19 pass for outbound international travel, though it added they would not be added to the domestic pass at this time. The Department of Health and Social Care said travellers who have had a booster or a third dose would be able to demonstrate their vaccine status through the NHS Covid Pass from today. The addition will enable those who have had their booster or third dose to travel to countries including Israel, Croatia and Austria who have already introduced a time limit for the Covid-19 vaccine to be valid for quarantine free travel. Booster and third doses will not be added to the domestic 'Covid Pass' as it is not a current requirement for individuals to receive booster doses to qualify as fully vaccinated. A booster is not necessary to travel into England.

Has the government in England learned nothing from the Covid-19 pandemic? Nigel Swift, Managing Director of Rowlands Pharmacy, part of Numark, the UK's largest pharmacy membership association, asks reflecting on the disorderly launch of this year's flu and Covid booster vaccination program as evidence to the contrary. "Community pharmacies play a crucial role in ensuring eligible individuals can easily access their free NHS flu and Covid vaccinations," Swift said, adding that delivering this essential service necessitates pharmacy staff allocating time for preparation and appointment scheduling. "Just a few weeks ago, NHSE informed us that the vaccination program would be postponed until October, prompting pharmacies to plan accordingly and notify patients," he said. "However, NHSE has now reversed its decision and set the program to commence on Sept. 11. Pharmacy recommended an earlier start, but NHSE opted for a delay instead, resulting in avoidable problems." On Aug. 30, NHSE announced plans to move up the start of the autumn vaccination drive in England to September 11, deviating from the initial October schedule, citing concerns about a new Covid-19 variant.

The National Pharmacy Association (NPA) views the COVID vaccination programme as broadly successful, largely due to the efforts of healthcare workers and volunteers. However, it cited some areas that could be improved, notably the early involvement of community pharmacies in planning, operational challenges, and recognising the role of community pharmacy in addressing vaccine hesitancy and inequalities. Submitting its evidence to the Covid-19 Inquiry, the NPA highlighted that the community pharmacy should have been consulted and involved earlier in the planning process, considering their two years of experience and expertise in administering annual influenza vaccination programs and the reach and resources of the 14,000 community pharmacies across the UK. "Instead, community pharmacy was initially given a gap in service role, which failed to fully utilize their experience, expertise and resource," Lawyer Brian Stanton told the Inquiry on behalf of the NPA during the Module 4 Preliminary Hearing on 22 May.

Johnson & Johnson said on Wednesday (January 18) that it was pulling the plug on a late-stage global trial of an HIV vaccine after the shot was found ineffective at preventing infections. The failure of the trial marks yet another setback in the search for a vaccine against a virus known to mutate rapidly and find unique ways to evade the immune system, and comes more than a year after another of J&J's HIV vaccine failed a study. "It's not the outcome we had hoped for, unfortunately," said a spokesperson for the National Institute of Allergy and Infectious Diseases, a J&J partner in the trial. "The development of a safe and effective HIV vaccine has been a considerable scientific challenge, but we will learn from this study and continue forward." The trial involved administering two different types of a shot, which uses a cold-causing virus to deliver the genetic code of HIV, spread over four vaccination visits in a year. J&J used similar technology for its COVID-19 vaccine. The study, which began in 2019, was conducted at over 50 sites and included about 3,900 gay men and transgender people - groups that are considered vulnerable to the infection.

Kate Bingham, the former head of the UK's Covid-19 Vaccine Taskforce who secured millions of doses for the country, said scientists should know within a week whether existing shots are effective against the Omicron variant of the coronavirus. Bingham, a venture capitalist who backed multiple vaccines at the start of the pandemic to secure early access for Britain, said she currently expected that the leading shots would still show efficacy. "The question is do they have the same level of efficacy?" she said on Wednesday. Bingham, who has returned to her role as managing partner at SV Health Investors, said Britain had built up the capability to quickly test existing vaccines against new variants. "It's not something you can do overnight, but we will get data, I would have thought within a week as to whether or not the vaccines work or don't," she said.

Healthcare workers, including community pharmacy staff, can book their Covid-19 booster vaccination through the National Booking Service from Wednesday (September 7) onwards. NHS England has announced that around seven million people, including those aged 75 and over, people who are immunosuppressed and health and care workers will be able to book an appointment for their Covid-19 booster vaccinations online or by calling 119. Eligible staff are encouraged to book an appointment for a booster dose as soon as possible, provided it has been at least three months since their last dose of the vaccine. "For other eligible patients (not health and care workers), invitations are being sent out and will be landing on their doormats from Wednesday 7th September inviting people to book their appointment for the following week without delay. The NHS will contact people when it is their turn to book in for the vaccine - there will be no need for patients to contact the NHS," said PSNC.

A pair of pharmacist brothers, who also own a popular restaurant in Kent, have started an innovative initiative 'Jabs with Kebabs' to encourage their community in England to come forward and take their Covid-19 vaccines. Rav and Raj Chopra, who own V's Punjabi Grill, an Indian restaurant in Gravesend, established the walk-in vaccine site after their father, Jagtar Chopra, became unwell with Covid-19 last year. The duo is among thousands to volunteer for the National Health Service (NHS) vaccine programme. Talking to the PA news agency, Raj said he was inspired by the experience of his father, who got infected with the virus and has fully recovered since then. "From a personal point of view, it was very debilitating to see Dad like that," said Raj Chopra. "It got everyone's emotions in play.

The Joint Committee on Vaccination and Immunisation (JCVI) on Thursday (May 19) said that an anticipated autumn Covid booster campaign would be aimed at people aged over 65, care home residents, frontline health and social care workers and all adults in a clinical risk group. The UK is offering a spring booster to the over-75s, care home residents and immunosuppressed people, and ministers have spoken openly of plans for a further booster campaign in the autumn. In interim advice, the JCVI stopped short of recommending another shot for all adults, though said the advice would be reviewed and updated. "The JCVI's current view is that in autumn 2022, a Covid-19 vaccine should be offered to: residents in a care home for older adults and staff; frontline health and social care workers; all those 65 years of age and over; and adults aged 16 to 64 years who are in a clinical risk group," the UK Health Security Agency said in a statement. Prime minister Boris Johnson, who was fiercely criticised for his handling of the early stages of the pandemic, lifted Covid restrictions in England in February, crediting Britain's quick initial vaccine rollout and the rollout of boosters with breaking the link between cases and deaths.